Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV000231124 | SCV000291948 | uncertain significance | not provided | 2014-03-04 | criteria provided, single submitter | clinical testing | The C13G variant has not been published as a mutation, nor has it been reported as a benign polymorphism to our knowledge. The C13G variant was not observed at a significant frequency in individuals of European and African American ancestry in the NHLBI Exome Sequencing Project, indicating it is not a common benign variant in these populations. The C13G variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs within the conserved FCH domain. However, the pathogenicity of missense changes in this region of the PSTPIP1 protein is unclear, as all currently known mutations associated with PAPA syndrome have been identified in the coiled-coil domain region. In silico analysis predicts this variant likely does not alter the protein structure/function. Therefore, based on the currently available information, it is unclear whether this variant is a pathogenic mutation or a rare benign variant. |
Invitae | RCV001514746 | SCV001722665 | benign | Pyogenic arthritis-pyoderma gangrenosum-acne syndrome | 2024-01-20 | criteria provided, single submitter | clinical testing | |
Genome Diagnostics Laboratory, |
RCV002262843 | SCV002542870 | uncertain significance | Autoinflammatory syndrome | 2018-07-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV002518394 | SCV003746093 | uncertain significance | Inborn genetic diseases | 2021-10-12 | criteria provided, single submitter | clinical testing | The c.37T>G (p.C13G) alteration is located in exon 2 (coding exon 2) of the PSTPIP1 gene. This alteration results from a T to G substitution at nucleotide position 37, causing the cysteine (C) at amino acid position 13 to be replaced by a glycine (G). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |